Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Benitec Biopharma Limited (BNTC : NSDQ)
 
 • Company Description   
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.

Number of Employees: 14

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.08 Daily Weekly Monthly
20 Day Moving Average: 24,804 shares
Shares Outstanding: 8.17 (millions)
Market Capitalization: $8.83 (millions)
Beta: 1.58
52 Week High: $5.07
52 Week Low: $1.04
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -46.80% -41.71%
12 Week -57.65% -54.04%
Year To Date -58.78% -50.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3940 Trust Way
-
Hayward,CA 94545
USA
ph: 510-780-0819
fax: 61 (0)3 9966-9923
jmorakis@mgroupsc.com http://www.benitec.com
 
 • General Corporate Information   
Officers
Jerel Banks - Chief Executive Officer; Director
Megan Boston - Director
J. Kevin Buchi - Director
Peter Francis - Director
Edward Smith - Director

Peer Information
Benitec Biopharma Limited (CORR.)
Benitec Biopharma Limited (RSPI)
Benitec Biopharma Limited (CGXP)
Benitec Biopharma Limited (BGEN)
Benitec Biopharma Limited (GTBP)
Benitec Biopharma Limited (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 08205P100
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/19/22
Share - Related Items
Shares Outstanding: 8.17
Most Recent Split Date: 4.00 (0.67:1)
Beta: 1.58
Market Capitalization: $8.83 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.08 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/19/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.81
Price/Cash Flow: -
Price / Sales: 149.58
EPS Growth
vs. Year Ago Period: 99.76%
vs. Previous Quarter: 99.66%
Sales Growth
vs. Year Ago Period: 4,700.00%
vs. Previous Quarter: 92.00%
ROE
03/31/22 - -111.03
12/31/21 - -124.21
09/30/21 - -106.22
ROA
03/31/22 - -96.62
12/31/21 - -106.68
09/30/21 - -95.13
Current Ratio
03/31/22 - -
12/31/21 - 5.11
09/30/21 - 10.23
Quick Ratio
03/31/22 - -
12/31/21 - 5.11
09/30/21 - 10.23
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -63,492.85
09/30/21 - -405,224.97
Book Value
03/31/22 - -
12/31/21 - 1.33
09/30/21 - 1.89
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.06
09/30/21 - 0.05
Debt-to-Capital
03/31/22 - -
12/31/21 - 6.05
09/30/21 - 4.68
 

Powered by Zacks Investment Research ©